Abstract
Although the arrival of investment opportunities increases the demand for information, it is also likely to exacerbate disclosure costs. This study examines the relationship between the arrival of investment opportunities and firm disclosures in the context of Medicare national coverage decisions (NCD), which create staggered changes to the investment opportunities available to different subsets of firms in the medical device industry. Consistent with disclosure costs being the dominant effect, we find that NCD approvals are associated with reductions in management forecasts, disclosures about R&D, and product-related announcements. Additional cross-sectional analyses suggest that greater reputation and proprietary cost concerns are important determinants of this negative association. We find that information intermediaries increase their coverage of firms following NCD approvals. Yet, overall, the greater investment opportunities due to NCD approvals appear to have a negative effect on firms’ information environment: NCD approvals are followed by higher analyst forecast dispersion, greater bid-ask spreads, and decreased stock liquidity.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
